TY  - JOUR
AU  - Felip, Enriqueta
AU  - Hirsh, Vera
AU  - Popat, Sanjay
AU  - Cobo, Manuel
AU  - Fülöp, Andrea
AU  - Dayen, Charles
AU  - Trigo, José M
AU  - Gregg, Richard
AU  - Waller, Cornelius F
AU  - Soria, Jean-Charles
AU  - Goss, Glenwood D
AU  - Gordon, James
AU  - Wang, Bushi
AU  - Palmer, Michael
AU  - Ehrnrooth, Eva
AU  - Gadgeel, Shirish M
PY  - 2017
DO  - 10.1016/j.cllc.2017.06.002
UR  - http://hdl.handle.net/10668/11425
T2  - Clinical lung cancer
AB  - In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based...
LA  - en
KW  - Cough
KW  - Diarrhea
KW  - Dyspnea
KW  - EGFR
KW  - Pain
KW  - Afatinib
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Squamous Cell
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Patient Reported Outcome Measures
KW  - Platinum Compounds
KW  - Quality of Life
KW  - Survival Analysis
TI  - Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
TY  - research article
VL  - 19
ER  -